JupiteX Get the app
Health & Medicine22 Nov 2026 · about 7 min

The Drugs Don’t Work

The brief

Antimicrobial resistance (AMR) means that germs causing infections are no longer stopped or killed by medicines that once worked against them. In this film, the focus is on resistance to antibiotics. The headline “The Drugs Don’t Work” describes the danger: an infection can become harder to treat when its usual medicine fails. The documentary shows what that risk means for patients and families, focusing on infant mortality in sub-Saharan Africa. It also follows the story to the United Kingdom, where it looks at penicillin, described as the world’s most successful antibiotic, and efforts to develop new solutions. The article says antibiotic overuse could fuel superbugs and lead to eight million deaths annually by 2050. It does not explain the biological process behind resistance. In general, resistance can emerge when some germs survive a drug and continue to spread. The film presents research, advocacy, and local innovation as parts of the wider response.

01

What does antimicrobial resistance mean when the headline says “the drugs don’t work”?

Antimicrobial resistance (AMR) means that germs causing infections are no longer stopped or killed by medicines that once worked against them. In this film, the focus is on resistance to antibiotics. The headline “The Drugs Don’t Work” describes the danger: an infection can become harder to treat when its usual medicine fails.

The documentary shows what that risk means for patients and families, focusing on infant mortality in sub-Saharan Africa. It also follows the story to the United Kingdom, where it looks at penicillin, described as the world’s most successful antibiotic, and efforts to develop new solutions.

The article says antibiotic overuse could fuel superbugs and lead to eight million deaths annually by 2050. It does not explain the biological process behind resistance. In general, resistance can emerge when some germs survive a drug and continue to spread. The film presents research, advocacy, and local innovation as parts of the wider response.

02

How many people could antimicrobial resistance kill each year by 2050?

The figure highlighted in the article is eight million people annually by 2050. It describes the possible scale of deaths linked to antibiotic overuse and the superbugs it could fuel. The wording matters: the article says “could,” so it presents a warning about a possible future, not a guaranteed count.

The documentary connects that large figure to people already facing the effects of antimicrobial resistance. It focuses especially on infant mortality in the developing world, specifically sub-Saharan Africa, and follows health workers and families struggling against the threat with low-tech solutions.

The film also looks at responses in the United Kingdom, including academic research and efforts to develop new antibiotics. Its closing return to Africa shows local innovation and tools from the developed world saving lives. The article says these efforts contribute to the global battle against resistance and could ultimately save millions, but it gives no further details about how the eight-million estimate was calculated.

03

What happens to patients when infections no longer respond to antibiotics?

When an infection no longer responds to an antibiotic, that medicine may not control the illness as expected. The infection can persist, and a patient may become seriously ill or die. This is the human danger behind the headline “The Drugs Don’t Work.” The article describes antimicrobial resistance as a growing threat, but does not set out specific symptoms or treatment outcomes for individual patients.

The film makes the consequences tangible by following health workers and families affected by resistance. It focuses on infant mortality in the developing world, specifically sub-Saharan Africa, where people are struggling to fight the problem with low-tech solutions. The article does not identify particular patients or infections.

It warns that antibiotic overuse could fuel superbugs, killing eight million people annually by 2050. That figure is a possible future toll, not a certainty. The film also shows research and local innovation as part of the effort to save lives. In general medical terms, infections that resist treatment can be more difficult to manage; that explanation is broader than the article’s specific examples.

04

Why are infants in sub-Saharan Africa especially affected by antimicrobial resistance?

The article identifies infant mortality in the developing world, specifically sub-Saharan Africa, as a place where the effects of antimicrobial resistance are acutely and tragically felt. It does not give a detailed explanation for why infants in that region are especially affected, so the film’s stated focus should not be mistaken for a full account of the causes.

As general health background, infants can be more vulnerable to serious infections because their bodies are still developing. When effective treatment is difficult to access, an infection that does not respond to antibiotics can pose an even greater danger. These are broad explanations, not specific causes established by the article for sub-Saharan Africa.

The documentary gives the issue a human face by following health workers and families as they fight the problem with low-tech solutions. It then shows local innovation and tools offered by the developed world saving lives in Africa. The article presents those efforts as part of the global response, but it does not name the particular tools or explain their effects on infant mortality.

05

How can local innovation and low-tech solutions help save lives where resistant infections are a threat?

Local innovation can help make responses to resistant infections more useful in the places where people need them. The article shows health workers and families in sub-Saharan Africa struggling against antimicrobial resistance with low-tech solutions. It does not list those solutions, so it offers no specific device, procedure, or project to point to as an example.

The film also describes tools offered by the developed world being used alongside local innovation. In broad terms, practical, accessible tools can support people working to fight infections. However, the article does not explain the tools’ exact mechanism or say whether they help with diagnosis, prevention, or treatment. Those details should not be assumed from the summary alone.

The outcome the article does state is that local innovation and these tools are now saving lives in Africa and contributing to the global battle against AMR. It presents this work as part of a wider effort that could ultimately save millions. The film’s message is that responses on the ground matter, while the precise approaches shown are not detailed in the supplied text.

06

Why are pharmaceutical companies struggling to develop new antibiotics?

The film asks why pharmaceutical companies like GlaxoSmithKline are struggling to produce novel solutions to antimicrobial resistance. The article identifies that difficulty but does not provide the company’s reasons, describe its research process, or say what has blocked particular projects.

As general industry background, developing a new medicine can require substantial research and testing, with no guarantee of success. Antibiotics also face a business challenge: when a new drug is held in reserve to slow resistance, it may be used less often, limiting sales. These points help explain the wider difficulty, but they are not reasons specified for GlaxoSmithKline in the article.

The documentary places the pharmaceutical challenge alongside research at British universities and hospitals, supported by the UK-based tech company DeepMind. It also features academics and advocates devoted to solving AMR. The article presents these efforts as part of a broader search for new solutions, while its return to Africa shows local innovation and developed-world tools already saving lives.

07

How does natural selection allow bacteria that survive antibiotics to spread?

Natural selection is a process in which traits that help an organism survive become more common over generations. In bacteria, some may already have traits that let them survive a particular antibiotic. This is general biology background; the article itself does not explain how bacterial resistance develops or spreads.

When an antibiotic is used, susceptible bacteria may be killed or stopped, while resistant ones survive. Those survivors can multiply, and resistance can become more common in the bacterial population. Resistant bacteria may also pass resistance traits to other bacteria. The article does not describe these steps, but they explain how antibiotic use can favor resistant germs.

The film’s stated concern is that antibiotic overuse could fuel superbugs and contribute to a possible eight million deaths annually by 2050. It follows efforts to develop new solutions, explores research at British universities and hospitals, and shows local innovation saving lives in Africa. The article frames AMR as a global battle, though it does not detail the biological mechanism.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web